Clinical Trial Update: Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating autologous/syngeneic stem cell transplant followed by donor stem cell transplant with bortezomib in newly diagnosed high-risk, relapsed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-18